Cansford Laboratories turns to HemaXis DB 10 for sampling in their PEth testing program

HemaXis DB 10 is Cansford Laboratories Ltd. solution for microsampling in their new PEth testing service. We are so proud to be part of this and contribute to improving patients health! 

Cansford Laboratories offers the UK’s fastest hair drug and alcohol testing service, while investing in research and development and contributing to conferences and symposia to drive up industry standards.

Link to Cansford blog : here

Zaragoza University uses HemaXis for Hg quantification

The group of Prof. Resano of Zaragoza University Department of Analytical Chemistry published a very interesting article about the use of HemaXis™ DB10 for the quantification of mercury in patients’ blood. The study showed excellent reproducibility for samples collected using HemaXis™ DB10. In the conclusion, the authors states that “current DBS microsampling devices show a very promising performance for Hg determination in whole blood, facilitating easy home collection”.

HemaXis™ DB10 tangibly opens the way to simpler and cheaper large population studies on heavy metal exposure!

Link to the original article

HemaXis DB 10 available at Cibesmed

If you need fully customised kits which could include device, disinfectant, lancet, plasters, envelope, etc. our partner Cibesmed (www.cibesmed.com) will be delighted to tailor a solution for you. You can send your request to

HemaXis DB 10 application presented in the German Symposium

Frank Sporkert & Cristian Palmiere will present, during the 15. Gemeinsames Symposium der Deutschen Gesellschaft für Verkehrspsychologie e. V. (DGVP) und der Deutschen Gesellschaft für Verkehrsmedizin e. V. (DGVM) in Bonn, very interesting data on Phosphatidylethanol and driving aptitude in the french-speaking part of Switzerland, measured from HemaXis DB 10.

Joining Lyonbiopôle

DBS System becomes member of Lyonbiopôle !

As a Cluster, Lyonbiopole is the gateway to healthcare innovation in the Auvergne-Rhône-Alpes region.

It’s supporting ambitious projects and innovative companies in the healthcare & life sciences’ sector. Its aim is to help innovators develop new technologies, products and services in a push toward a more personalized medicine and better treatments for patients.lyonbiopole logo

HemaXis™ DB10 samples professional cyclists in drug monitoring program

DBS System SA today announced its collaboration with the Union Cycliste Internationale (UCI) and the Center of Research and Expertise in anti-Doping sciences (REDs) to monitor the use of Tramadol in the professional peloton. Following the ban of Tramadol use on March 1, the drug has been tested on 143 samples of 117 professional riders at 11 major events on the UCI WorldTour Calendar.

Blood samples have been collected with HemaXis™ DB10, the patented blood collection device manufactured by DBS System SA, a company based in Switzerland. HemaXis DB10 generates reliable blood microsamples straight from the rider’s finger-tip in an instantaneous, user-friendly and cost-effective manner.

HemaXis™ uniquely allows the convenient collection and storage of an accurate quantity of blood in the form of dried blood spots. These standardized dried blood spots enable a dependable analysis, while reducing overall cost and logistic constraints.

“We are proud to announce that HemaXis™ contributes to the health and safety of the competitors.” said Eric Ödman, CEO of DBS System. “We firmly believe that our technology will be the way forward for much improved monitoring of drug use in sport.”

UCI press release available at https://www.uci.org/inside-uci/press-releases/misuse-of-tramadol-uci-report-on-tests-carried-out-during-the-first-part-of-the-2019-season

DBS System’s HemaXis™ DB 10 blood collection device is now CE/IVD marked

DBS System SA announced today that its blood collection device, HemaXis™ DB 10, has been registered with the Swiss Agency for Therapeutic Products (SwissMedic), and is now CE/IVD marked following the 98/79/EC In vitro Diagnostic Medical Device Directive. HemaXis DB 10 is DBS System’s first-generation device for the collection, transport and storage of a precisely metered quantity of capillary whole blood sample, through a prick at the patient’s fingertip.

DBS System, a Swiss based company, produces blood collection devices that leverage advanced microfluidic technology to simplify and reduce the cost of blood sampling without the need to significantly modify existing laboratory workflows. With the CE mark applied on HemaXis™ DB 10, DBS System will target sales to certified labs performing analysis for clinical trials, diagnostic and wellness testing to monitor health, offering a simple, less invasive and highly cost-efficient alternative to traditional blood collection, thereby overcoming the worldwide challenges blood collection has faced for decades.

DBS System’s device uniquely allows for the patient friendly and standardized collection and storage of an accurate quantity of whole blood. The integration of an industry standard filter paper card for sample storage enables fully automated extraction and analysis using existing equipment. In addition, HemaXis™ DB 10 simplifies the logistics chain because cold storage is not required, resulting in significant cost savings for labs. These benefits provide a clear advantage over traditional dried blood spot collection and competitive devices being launched in the market.

Obtaining the CE mark is a major milestone for DBS System as it will enable us to penetrate the European market by building strong partnerships and a platform for growth in Switzerland and Europe. Coupled with the already secured FDA clearance for the US market, we are now in a position to engage several major research and commercial labs across the two biggest markets of the world, in exciting and growing areas such as wellness testing for preventative care and for alcohol and drugs of abuse screening especially in context of the current opioid epidemic”, says CEO Eric Ödman.

Efficient Alcohol Consumption Monitoring

PEth testing is quickly becoming the preferred choice for alcohol consumption monitoring and HemaXis DB offers a complete solution to simplify and improve the PEth testing process. View a summary of the benefits of using HemaXis DB with PEth testing for efficient alcohol consumption monitoring and download an application note developed with ACQ Science to get detailed information on adding PEth testing with HemaXis DB into your workflow.

Links:
PEth Testing page
Application Note

 

HemaXis DB launched in the U.S. with FDA listing

DBS System has launched their HemaXis DB micro blood collection device in the United States with an FDA Class 1 medical device listing. HemaXis DB is DBS System’s first generation device for the collection, transport and storage of capillary whole blood samples. DBS System, a Swiss based company, produces blood collection devices that leverage advanced microfluidic technology to simplify and reduce the cost of blood sampling without the need to modify existing laboratory workflows. With its U.S. market launch, DBS System will target sales to certified labs performing analysis for pre-clinical trials, pre-diagnostic and wellness testing to monitor health.

HemaXis DB offers a complete and practical solution to collect precise volumes of capillary whole blood at the fingertip with levels of standardization and reliability comparable to a micropipette. The integration of an industry standard filter card for sample storage enables fully automated extraction and analysis using existing equipment. In addition, the function and design of HemaXis DB simplifies the logistics chain because cold storage is not required and it fits within the existing laboratory workflow, all together resulting in significant cost savings for labs. These benefits provide a clear advantage over traditional dried blood spot collection and competitive devices being launched in the market.

“The FDA listing is an important milestone for DBS System as it will enable us to build strong partnerships and a platform for growth in the U.S., where the estimated yearly addressable market size for blood testing is USD 8 Billion. We have several U.S. researchers and commercial labs that have evaluated HemaXis DB in exciting and growing areas such as wellness testing for preventative care and for alcohol and drugs of abuse screening especially in context of the current opioid epidemic”, says CEO Eric Ödman. To drive rapid adoption of the HemaXis DB device, DBS System’s team of scientists also provide analytical method support to help implement HemaXis into customer labs workflow.

Last year, DBS System raised 2.5M CHF (approx. 2.5M USD) to industrialize it’s second generation HemaXis DX device that passively separates plasma or serum from whole blood, thus dramatically increasing the range of tests capable of being run on dried blood samples. DBS System aims to establish itself as the leading manufacturer of medical devices for collecting and preparing micro samples of whole blood, plasma and serum with its patented HemaXis™ platform of microfluidic devices.

USPTO Patent Granted For HemaXis Microfluidic Blood Collection Platform

We are proud to announce the USPTO patent covering our 1st Generation micro blood collection device, HemaXis DB, has been fully granted under “Device and Method for Dried Fluid Spot Analysis”. This further secures the market potential for our innovative HemaXis™ platform and the opportunity to leverage its microfluidic based technology. See HemaXis DB in action below and then register with us under the Connect menu option to order a free evaluation kit.